Brazil's President signs anti-bribery statute
As largely expected, Brazilian President Dilma Rousseff has signed the Brazilian Clean Companies Act, according to a comprehensive report from law firm Covington & Burling, which, though not specifically targeted as the sector, will clearly have implications for pharmaceutical companies, both domestic firms and multinationals doing business in that country.
The Act subjects for the first time Brazilian companies and other Brazilian entities plus foreign entities having a registered office, branch or other representation in the Brazilian territory to civil and administrative sanctions for bribing either Brazilian or foreign public officials. The Act, which is scheduled to take effect on January 29, 2014, also applies to fraud in relation to public tenders.
Heavy financial penalties
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze